Literature DB >> 9144231

Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease.

S Du Yan1, H Zhu, J Fu, S F Yan, A Roher, W W Tourtellotte, T Rajavashisth, X Chen, G C Godman, D Stern, A M Schmidt.   

Abstract

In Alzheimer disease (AD), neurons are thought to be subjected to the deleterious cytotoxic effects of activated microglia. We demonstrate that binding of amyloid-beta peptide (Abeta) to neuronal Receptor for Advanced Glycation Endproduct (RAGE), a cell surface receptor for Abeta, induces macrophage-colony stimulating factor (M-CSF) by an oxidant sensitive, nuclear factor kappaB-dependent pathway. AD brain shows increased neuronal expression of M-CSF in proximity to Abeta deposits, and in cerebrospinal fluid from AD patients there was approximately 5-fold increased M-CSF antigen (P < 0.01), compared with age-matched controls. M-CSF released by Abeta-stimulated neurons interacts with its cognate receptor, c-fms, on microglia, thereby triggering chemotaxis, cell proliferation, increased expression of the macrophage scavenger receptor and apolipoprotein E, and enhanced survival of microglia exposed to Abeta, consistent with pathologic findings in AD. These data delineate an inflammatory pathway triggered by engagement of Abeta on neuronal RAGE. We suggest that M-CSF, thus generated, contributes to the pathogenesis of AD, and that M-CSF in cerebrospinal fluid might provide a means for monitoring neuronal perturbation at an early stage in AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144231      PMCID: PMC24672          DOI: 10.1073/pnas.94.10.5296

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.

Authors:  J Brett; A M Schmidt; S D Yan; Y S Zou; E Weidman; D Pinsky; R Nowygrod; M Neeper; C Przysiecki; A Shaw
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

Review 2.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

3.  Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease.

Authors:  M A Smith; R K Kutty; P L Richey; S D Yan; D Stern; G J Chader; B Wiggert; R B Petersen; G Perry
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

4.  A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease.

Authors:  K Hensley; J M Carney; M P Mattson; M Aksenova; M Harris; J F Wu; R A Floyd; D A Butterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

5.  Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.

Authors:  S D Yan; X Chen; A M Schmidt; J Brett; G Godman; Y S Zou; C W Scott; C Caputo; T Frappier; M A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

6.  Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer's disease and amyotrophic lateral sclerosis.

Authors:  H Akiyama; T Nishimura; H Kondo; K Ikeda; Y Hayashi; P L McGeer
Journal:  Brain Res       Date:  1994-03-07       Impact factor: 3.252

7.  Activation of macrophages by Alzheimer beta amyloid peptide.

Authors:  A Klegeris; D G Walker; P L McGeer
Journal:  Biochem Biophys Res Commun       Date:  1994-03-15       Impact factor: 3.575

8.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.

Authors:  A E Roher; J D Lowenson; S Clarke; A S Woods; R J Cotter; E Gowing; M J Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

9.  Hydrogen peroxide mediates amyloid beta protein toxicity.

Authors:  C Behl; J B Davis; R Lesley; D Schubert
Journal:  Cell       Date:  1994-06-17       Impact factor: 41.582

Review 10.  The Alzheimer's disease sphinx: a riddle with plaques and tangles.

Authors:  K S Kosik
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  113 in total

1.  Microglia in Alzheimer's disease and transgenic models. How close the fit?

Authors:  D W Dickson
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 2.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

Review 3.  Cellular cofactors for amyloid beta-peptide-induced cell stress. Moving from cell culture to in vivo.

Authors:  S D Yan; A Roher; A M Schmidt; D M Stern
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

4.  Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.

Authors:  Ricardo Gomes; Marta Sousa Silva; Alexandre Quintas; Carlos Cordeiro; António Freire; Paulino Pereira; Américo Martins; Estela Monteiro; Eduardo Barroso; Ana Ponces Freire
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

5.  Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex.

Authors:  Nicola Origlia; Camilla Bonadonna; Alfredo Rosellini; Elena Leznik; Ottavio Arancio; Shirley Shidu Yan; Luciano Domenici
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

6.  PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease.

Authors:  Marwan N Sabbagh; Albert Agro; Joanne Bell; Paul S Aisen; Edward Schweizer; Douglas Galasko
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Jul-Sep       Impact factor: 2.703

7.  The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells.

Authors:  Huan Du; Pengtao Li; Jun Wang; Xuemei Qing; Weihong Li
Journal:  Cell Mol Neurobiol       Date:  2011-08-12       Impact factor: 5.046

Review 8.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

9.  RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.

Authors:  Fang Fang; Lih-Fen Lue; Shiqiang Yan; Hongwei Xu; John S Luddy; Doris Chen; Douglas G Walker; David M Stern; Shifang Yan; Ann Marie Schmidt; John X Chen; Shirley ShiDu Yan
Journal:  FASEB J       Date:  2009-11-11       Impact factor: 5.191

10.  Association between the RAGE G82S polymorphism and Alzheimer's disease.

Authors:  Keshen Li; Dawei Dai; Bin Zhao; Lifen Yao; Songpo Yao; Binyou Wang; Ze Yang
Journal:  J Neural Transm (Vienna)       Date:  2009-11-10       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.